BPMC - Blueprint Medicines Corp Stock Price, Fair Value and News

108.66USD+0.11 (+0.10%)Market Closed

Market Summary

USD108.66+0.11

Market Closed

0.10%

BPMC Alerts

2 major insider sales recently.

Big jump in Revenue (Y/Y)
Big jump in Earnings (Y/Y)

BPMC Stock Price

View Fullscreen

BPMC RSI Chart

BPMC Valuation

Market Cap

6.8B

Price/Earnings (Trailing)

-23.6

Price/Sales (Trailing)

24.11

EV/EBITDA

-24.42

Price/Free Cashflow

-15.82

BPMC Price/Sales (Trailing)

BPMC Profitability

EBT Margin

-101.93%

Return on Equity

-92.79%

Return on Assets

-27.76%

Free Cashflow Yield

-6.32%

BPMC Fundamentals

BPMC Revenue

Revenue (TTM)

282.2M

Rev. Growth (Yr)

51.87%

Rev. Growth (Qtr)

33.57%

BPMC Earnings

Earnings (TTM)

-288.3M

Earnings Growth (Yr)

168.8%

Earnings Growth (Qtr)

180.36%

Breaking Down BPMC Revenue

Last 7 days

14.6%

Last 30 days

18.7%

Last 90 days

46.5%

Trailing 12 Months

100.4%

How does BPMC drawdown profile look like?

BPMC Financial Health

Current Ratio

3.76

BPMC Investor Care

Shares Dilution (1Y)

3.55%

Diluted EPS (TTM)

-4.82

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	282.2M	0	0	0
2023	204.6M	225.6M	216.2M	249.4M
2022	221.2M	230.5M	272.3M	204.0M
2021	640.3M	486.9M	333.5M	180.1M
2020	71.9M	312.5M	553.1M	793.7M
2019	50.0M	55.5M	61.0M	66.5M
2018	27.2M	33.0M	38.7M	44.5M
2017	26.8M	25.6M	27.5M	21.4M
2016	17.6M	22.0M	24.7M	27.8M
2015	0	0	0	11.4M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Blueprint Medicines Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 02, 2024	landsittel michael	sold	-1,050,000	105	-10,000	chief financial officer
May 02, 2024	landsittel michael	acquired	360,500	36.05	10,000	chief financial officer
May 02, 2024	hurley ariel	acquired	99,274	54.13	1,834	principal accounting officer
May 02, 2024	hurley ariel	sold	-190,516	103	-1,834	principal accounting officer
Mar 28, 2024	landsittel michael	acquired	180,250	36.05	5,000	chief financial officer
Mar 28, 2024	landsittel michael	sold	-475,000	95.00	-5,000	chief financial officer
Mar 20, 2024	albers jeffrey w.	sold	-2,188,260	87.2757	-25,073	-
Mar 20, 2024	albers jeffrey w.	acquired	178,287	7.1107	25,073	-
Mar 15, 2024	hurley ariel	acquired	12,008	15.01	800	principal accounting officer
Mar 15, 2024	landsittel michael	acquired	180,250	36.05	5,000	chief financial officer

Which funds bought or sold BPMC recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	Headlands Technologies LLC	added	105	33,294	63,272	0.01%
May 07, 2024	SEI INVESTMENTS CO	added	36.64	1,255,550	4,354,650	0.01%
May 07, 2024	SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC	new	-	474,300	474,300	0.02%
May 07, 2024	NEW YORK STATE COMMON RETIREMENT FUND	added	6.83	314,000	3,489,000	-%
May 07, 2024	Susquehanna Portfolio Strategies, LLC	unchanged	-	256,281	9,278,920	0.22%
May 07, 2024	MEEDER ASSET MANAGEMENT INC	new	-	2,941	2,941	-%
May 07, 2024	ClariVest Asset Management LLC	reduced	-0.52	43,294	1,918,160	0.20%
May 07, 2024	PANAGORA ASSET MANAGEMENT INC	reduced	-2.6	41,302	24,993,100	0.13%
May 07, 2024	Arizona State Retirement System	reduced	-1.49	19,444	1,505,520	0.01%
May 07, 2024	Swiss National Bank	added	0.44	344,800	10,814,000	0.01%

Are Funds Buying or Selling BPMC?

Are funds buying BPMC calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BPMC

No. of Funds

Unveiling Blueprint Medicines Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 10, 2024	price t rowe associates inc /md/	10.2%	6,250,823	SC 13G/A
Feb 14, 2024	price t rowe associates inc /md/	8.9%	5,435,617	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 08, 2024	wellington management group llp	7.03%	4,276,333	SC 13G/A
Jan 24, 2024	blackrock inc.	10.8%	6,584,176	SC 13G/A
Jan 10, 2024	vanguard group inc	10.06%	6,114,970	SC 13G/A
Nov 13, 2023	fmr llc	-	0	SC 13G/A
Feb 14, 2023	price t rowe associates inc /md/	7.2%	4,299,290	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	9.65%	5,774,456	SC 13G/A

Recent SEC filings of Blueprint Medicines Corp

View All Filings

Date Filed	Form Type	Document
May 06, 2024	4	Insider Trading
May 06, 2024	4	Insider Trading
May 02, 2024	10-Q	Quarterly Report
May 02, 2024	144	Notice of Insider Sale Intent
May 02, 2024	144	Notice of Insider Sale Intent
May 02, 2024	8-K	Current Report
Apr 25, 2024	8-K	Current Report
Apr 25, 2024	ARS	ARS
Apr 25, 2024	DEF 14A	DEF 14A
Apr 10, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Blueprint Medicines Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	46.7B	6.8B	16.03%	-8.84%	-7.83	6.82	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.3B	2.0B	-2.41%	-26.73%	-58.01	9.62	75.20%	68.82%
BMRN	15.5B	2.5B	-6.28%	-14.44%	75.6	6.28	13.74%	186.89%
INCY	12.0B	3.8B	-2.82%	-17.40%	16.12	3.19	8.58%	129.81%
MID-CAP
BBIO	5.2B	107.9M	-2.02%	101.31%	-9.48	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-21.41%	-52.73%	-12.3	9.79	394.93%	39.61%
AXSM	3.6B	251.0M	5.14%	-1.20%	-12.15	14.35	73.58%	-86.73%
ARWR	3.1B	240.7M	-1.87%	-37.68%	-10.53	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-3.99%	-20.25%	-45.95	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	411.3M	-5.16%	-15.46%	26.68	4.22	60.38%	-34.49%
NVAX	625.6M	983.7M	0.90%	-53.05%	-1.15	0.64	-50.36%	17.16%
CRBP	451.6M	881.7K	5.23%	376.44%	-13.38	481.06	-77.61%	33.36%
INO	257.1M	4.9M	-3.00%	9.13%	-1.9	52.83	-54.97%	51.71%
IBIO	6.6M	2.1M	-15.93%	74.31%	-0.24	2.14	-13.45%	66.37%

Blueprint Medicines Corp News

Latest updates

Blueprint Medicines Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	33.6%	96,116,000	71,957,000	56,566,000	57,570,000	63,287,000	38,781,000	65,977,000	36,547,000	62,731,000	107,021,000	24,188,000	27,295,000	30,700,500	34,106,000	745,118,000	375,642,500	6,167,000	51,533,000	9,139,000	5,110,000	3,071,500
Costs and Expenses	-1.2%	174,939,000	177,066,000	185,546,000	185,551,000	187,494,000	188,580,000	190,254,000	194,185,000	168,535,000	423,157,000	141,284,000	135,806,000	121,814,000	120,072,000	111,751,000	133,380,000	119,825,000	120,911,000	107,100,000	109,024,000	90,803,000
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	120,911,000	107,100,000	109,024,000	90,803,000
S&GA Expenses	3.9%	83,557,000	80,417,000	70,741,000	71,931,000	70,950,000	64,020,000	57,608,000	58,688,000	57,058,000	54,199,500	49,806,000	49,286,000	42,002,000	42,539,500	37,375,000	42,174,000	35,655,000	32,265,000	25,647,000	21,923,000	16,553,000
R&D Expenses	-8.5%	88,191,000	96,434,000	110,252,000	110,063,000	112,073,000	117,839,500	127,981,000	128,466,000	103,133,000	356,876,500	84,419,000	80,027,000	79,710,000	77,404,500	74,230,000	91,079,000	84,146,000	88,646,000	81,453,000	87,101,000	74,250,000
EBITDA Margin	52.9%	-0.97	-2.06	-2.58	-2.50	-2.86	-2.73	-2.61	-2.98	-2.89	-3.51	-1.20	0.72	0.53	-	-	-	-	-	-	-	-
Interest Expenses	376.2%	14,280,000	-5,169,500	-3,808,000	-3,996,000	-5,819,000	-9,240,000	-8,396,000	427,000	442,000	463,000	552,000	633,000	738,000	936,000	1,173,000	1,586,000	2,904,000	2,989,500	3,758,000	4,275,000	2,710,000
Income Taxes	146.6%	180,000	73,000	200,000	190,000	500,000	1,029,000	900,000	3,130,000	184,000	2,346,000	175,000	193,000	574,000	688,000	370,000	15,000	32,000	55,000	33,000	44,000	53,000
Earnings Before Taxes	180.6%	89,316,000	-110,856,000	-133,516,000	-132,603,000	-129,040,000	-157,610,000	-132,277,000	-156,579,000	-105,815,000	-316,053,000	-117,066,000	-108,251,000	-99,714,000	-84,980,000	634,348,000	-123,474,000	-	-	-94,275,000	-	-
EBT Margin	49.8%	-1.02	-2.03	-2.56	-2.44	-2.81	-2.71	-2.61	-3.02	-2.93	-3.56	-1.23	0.70	0.51	-	-	-	-	-	-	-	-
Net Income	180.4%	89,136,000	-110,916,500	-133,713,000	-132,794,000	-129,560,000	-158,646,000	-133,163,000	-159,709,000	-105,999,000	-318,686,000	-117,241,000	-108,444,000	-99,714,000	-85,668,500	633,978,000	-123,474,000	-110,953,000	-66,331,000	-94,275,000	-99,681,000	-87,407,000
Net Income Margin	49.8%	-1.02	-2.03	-2.57	-2.46	-2.84	-2.73	-2.64	-3.04	-2.94	-3.58	-1.23	0.70	0.51	-	-	-	-	-	-	-	-
Free Cashflow	-22.7%	-102,617,000	-83,601,000	-110,734,000	-133,029,000	-125,545,000	-122,886,000	-133,619,000	-120,812,000	-133,879,000	-15,372,000	-96,592,000	-63,827,000	-125,951,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-1.0%	1,038	1,049	1,105	1,106	1,220	1,350	1,458	1,192	1,143	1,252	1,477	1,569	1,625	1,718	1,558	817	914	708	738	807	545
Current Assets	-3.9%	777	808	808	811	900	1,047	1,228	952	687	554	772	704	938	928	842	568	705	517	514	613	427
Cash Equivalents	73.9%	124	71.00	56.00	76.00	170	120	291	173	37.00	210	554	534	698	690	565	289	375	120	89.00	82.00	79.00
Inventory	45.8%	31.00	21.00	16.00	17.00	18.00	30.00	35.00	35.00	30.00	22.00	17.00	15.00	16.00	9.00	6.00	4.00	3.00	-	-	-	-
Net PPE	0.0%	42.00	42.00	41.00	37.00	34.00	33.00	33.00	33.00	31.00	31.00	31.00	32.00	33.00	34.00	35.00	37.00	38.00	38.00	38.00	34.00	31.00
Liabilities	-20.8%	728	919	903	795	806	835	818	445	262	281	230	240	225	248	238	236	231	243	222	214	200
Current Liabilities	-3.9%	207	215	197	169	173	183	176	159	137	150	120	125	112	131	110	105	98.00	106	94.00	82.00	65.00
LT Debt, Current	-	-	-	-	-	-	-	-	6.00	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	166	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	137.9%	311	131	203	311	414	515	640	748	882	971	1,247	1,329	1,400	1,470	1,320	581	683	464	516	593	344
Retained Earnings	3.8%	-2,250	-2,339	-2,229	-2,095	-1,962	-1,832	-1,674	-1,541	-1,381	-1,275	-956	-839	-731	-631	-545	-1,179	-1,056	-945	-878	-784	-684
Additional Paid-In Capital	3.7%	2,565	2,474	2,434	2,411	2,381	2,358	2,329	2,303	2,275	2,250	2,209	2,174	2,136	2,107	1,868	1,762	1,739	1,412	1,395	1,376	1,029
Shares Outstanding	2.4%	63.00	61.00	61.00	61.00	60.00	60.00	60.00	60.00	59.00	59.00	59.00	58.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	3,803	-	-	-	3,004	-	-	-	5,150	-	-	-	4,234	-	-	-	4,628	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-28.6%	-101	-78.93	-104	-130	-122	-121	-129	-118	-132	-14.11	-95.60	-63.16	-125	-24.80	622	-101	-109	-44.89	-71.70	-81.23	-80.19
Share Based Compensation	7.3%	24.00	23.00	23.00	24.00	23.00	26.00	24.00	25.00	23.00	23.00	24.00	24.00	21.00	20.00	20.00	20.00	17.00	16.00	15.00	14.00	10.00
Cashflow From Investing	-2.1%	77.00	79.00	-9.59	32.00	173	-53.28	-132	77.00	-41.09	-346	104	-115	132	-75.53	-430	12.00	60.00	68.00	75.00	-248	89.00
Cashflow From Financing	331.2%	67.00	16.00	98.00	-	-	2.00	381	177	1.00	18.00	11.00	15.00	7.00	220	84.00	3.00	310	2.00	4.00	332	2.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BPMC Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Revenue	$ 96,116	$ 63,287
Cost and operating expenses:
Cost of sales	3,191	3,175
Research and development	88,191	112,073
Selling, general and administrative	83,557	70,950
Collaboration loss sharing		1,296
Total cost and operating expenses	174,939	187,494
Other income (expense):
Interest expense, net	(5,895)	(5,819)
Other income, net	376	986
Debt extinguishment gain	173,658
Total other income (expense), net	168,139	(4,833)
Income (loss) before income taxes	89,316	(129,040)
Income tax expense	180	520
Net income (loss)	89,136	(129,560)
Other comprehensive income (loss):
Unrealized gains (losses) on available-for-sale investments	(564)	5,819
Currency translation adjustments	212	22
Comprehensive income (loss)	$ 88,784	$ (123,719)
Net income (loss) per share - basic (in dollars per share)	$ 1.45	$ (2.15)
Net income (loss) per share - diluted (in dollars per share)	$ 1.40	$ (2.15)
Weighted-average number of common shares used in net income (loss) per share - basic (in shares)	61,580	60,126
Weighted-average number of common shares used in net income (loss) per share - diluted (in shares)	63,802	60,126
Product revenue, net
Revenues:
Revenue	$ 92,525	$ 39,069
Collaboration and License
Revenues:
Revenue	$ 3,591	$ 24,218

BPMC Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 113,326	$ 71,286
Marketable securities	534,575	639,355
Accounts receivable	60,047	42,827
Inventory	30,940	21,223
Prepaid expenses and other current assets	37,714	33,702
Total current assets	776,602	808,393
Marketable securities	87,703	56,530
Property and equipment, net	41,947	41,959
Operating lease right-of-use assets, net	71,222	73,691
Restricted cash	10,634	10,238
Equity investment	27,789	27,789
Other assets	22,578	30,650
Total assets	1,038,475	1,049,250
Current liabilities:
Accounts payable	4,926	4,710
Accrued expenses	107,277	127,992
Current portion of operating lease liabilities	12,240	11,933
Current portion of deferred revenue	7,251	812
Current portion of liabilities related to the sale of future royalties and revenues	44,729	39,198
Current portion of term loan	30,180	30,278
Total current liabilities	206,603	214,923
Operating lease liabilities, net of current portion	78,489	81,751
Deferred revenue, net of current portion	4,635	4,792
Liabilities related to the sale of future royalties and revenues, net of current portion	223,090	402,427
Term loan, net of current portion	209,205	208,535
Other long-term liabilities	5,766	6,213
Total liabilities	727,788	918,641
Commitments and Contingencies (Note 16)
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 120,000,000 shares authorized; 62,594,247 and 61,147,236 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	63	61
Additional paid-in capital	2,565,277	2,473,985
Accumulated other comprehensive loss	(3,847)	(3,495)
Accumulated deficit	(2,250,806)	(2,339,942)
Total stockholders' equity	310,687	130,609
Total liabilities and stockholders' equity	$ 1,038,475	$ 1,049,250

About Blueprint Medicines Corp

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and Fisogatinib. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

CEO	Ms. Kathryn Haviland
WEBSITE	blueprintmedicines.com
INDUSTRY	Biotechnology
EMPLOYEES	660

Blueprint Medicines Corp Frequently Asked Questions

What is the ticker symbol for Blueprint Medicines Corp? What does BPMC stand for in stocks?

BPMC is the stock ticker symbol of Blueprint Medicines Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Blueprint Medicines Corp (BPMC)?

As of Wed May 08 2024, market cap of Blueprint Medicines Corp is 6.8 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BPMC stock?

You can check BPMC's fair value in chart for subscribers.

What is the fair value of BPMC stock?

You can check BPMC's fair value in chart for subscribers. The fair value of Blueprint Medicines Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Blueprint Medicines Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BPMC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Blueprint Medicines Corp a good stock to buy?

The fair value guage provides a quick view whether BPMC is over valued or under valued. Whether Blueprint Medicines Corp is cheap or expensive depends on the assumptions which impact Blueprint Medicines Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BPMC.

What is Blueprint Medicines Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, BPMC's PE ratio (Price to Earnings) is -23.6 and Price to Sales (PS) ratio is 24.11. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BPMC PE ratio will change depending on the future growth rate expectations of investors.